Different clinical response to interferon beta and glatiramer acetate related to the presence of oligoclonal IgM bands in CSF in multiple sclerosis patients


Por: Casanova, B, Lacruz, L, Villar, M, Dominguez, J, Gadea, M, Gascon, F, Mallada, J, Hervas, D, Simo-Castello, M, Alvarez-Cermeno, J, Calles, C, Olascoaga, J, Ramio-Torrenta, L, Alcala, C, Cervello, A, Bosca, I, Perez-Mirallles, F and Coret, F

Publicada: 1 ago 2018
Resumen:
To study the efficacy of interferon beta (IFN beta) and glatiramer acetate (GA) related to the presence of oligoclonal M bands (OCMB) in the cerebrospinal fluid in relapsing-remitting multiple sclerosis (RRMS). This is an observational, multicenter and retrospective study with prospectively collected data of patients that started treatment with IFN beta or GA. Treatment decision was made blinded to the OCMB status. Time to first attack after starting therapy was compared by using Kaplan-Meier curves, and adjustment by Cox regression analysis was performed. Two hundred and fifty-six patients entered in the study (141-55% received IFN beta; 115-45% received GA). After a mean follow-up of 41 and 65 months, 54.7% of patients remained free from further attacks (RF). The proportion of RF patients was higher in the GA group than in the IFN beta group (72.2 vs. 40.4%, p < 0.001). The IFN beta patients with OCMB+ presented the poorest response, 31.3% RF vs. 48.1% in IFN beta without OCMB, p = 0.03. OCMB in CSF could be a biomarker of treatment response in multiple sclerosis.

Filiaciones:
Casanova, B:
 Hosp Univ & Politecn La Fe, Neuroimmunol Unit, Valencia, Spain

Lacruz, L:
 Hosp Univ & Politecn La Fe, Neuroimmunol Unit, Valencia, Spain

Villar, M:
 Hosp Ramon y Cajal Madrid, Serv Immunol, Madrid, Spain

Dominguez, J:
 Hosp Clin Univ Valencia, Neuroimmunol Unit, Valencia, Spain

Gadea, M:
 Hosp Gen Valencia, Neurol Serv, Valencia, Spain

Gascon, F:
 Hosp Clin Univ Valencia, Neuroimmunol Unit, Valencia, Spain

:
 Hosp Elda, Neurol Serv, Alicante, Spain

Hervas, D:
 Inst Invest Sanitaria La Fe, Biostat Unit, Valencia, Spain

Alvarez-Cermeno, J:
 Hosp Ramon y Cajal Madrid, Neurol Serv, Madrid, Spain

Calles, C:
 Hosp Son Espases, Neurol Serv, Mallorca, Spain

Olascoaga, J:
 Hosp Donosti, Neurol Serv, San Sebastian, Spain

Ramio-Torrenta, L:
 Hosp Dr Josep Trueta, Neuroimmunol & Multiple Sclerosis Unit, IDIBGI, Girona, Spain

Alcala, C:
 Hosp Univ & Politecn La Fe, Neuroimmunol Unit, Valencia, Spain

Cervello, A:
 Hosp Gen Valencia, Neurol Serv, Valencia, Spain

Bosca, I:
 Hosp Univ & Politecn La Fe, Neuroimmunol Unit, Valencia, Spain

Perez-Mirallles, F:
 Hosp Univ & Politecn La Fe, Neuroimmunol Unit, Valencia, Spain

Coret, F:
 Hosp Clin Univ Valencia, Neuroimmunol Unit, Valencia, Spain
ISSN: 15901874





NEUROLOGICAL SCIENCES
Editorial
SPRINGER-VERLAG ITALIA SRL, VIA DECEMBRIO, 28, MILAN, 20137, ITALY, Italia
Tipo de documento: Article
Volumen: 39 Número: 8
Páginas: 1423-1430
WOS Id: 000439465800013
ID de PubMed: 29882169

MÉTRICAS